Notable Stock to Watch: ESSA Pharma Inc. (NASDAQ:EPIX)

 ESSA Pharma Inc. (NASDAQ:EPIX) spotted trading -13.78% off 52-week high price. On the other end, the stock has been noted 175.18% away from the low price over the last 52-weeks. The stock changed 8.23% to recent value of $3.88. The stock transacted 35085 shares during most recent day however it has an average volume of 38.06K shares. The company has 20.76M of outstanding shares and 7.61M shares were floated in the market.  

On Oct.18, 2019, ESSA Pharma Inc. (NASDAQ:EPIX) a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, released that Ari Brettman has been appointed to the board of the directors of the Company (the Board) pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments. 

David R. Parkinson, President and Chief Executive Officer, said, We are extremely appreciative of Otello’s support as a member of the Board of Directors.  Ari’s perspectives will be valuable as we execute on the path towards a successful IND filing of EPI-7386.

Dr. Brettman is currently a Principal in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Brettman joined Clarus in September 2014. Dr. Brettman is currently a member of the Board of Directors of Praxis Precision Medicines and Anthos Therapeutics as well as an Observer on the Board of Directors of Talaris Therapeutics.

Dr. Brettman completed a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital (MGH) and was also a National Institutes of Health-sponsored post-doctoral fellow at the MGH Center for Systems Biology. He received his M.D. from Duke University and his A.B. in History and Science from Harvard College. While a medical student, he was a Sarnoff Cardiovascular Research Foundation Fellow at Stanford University, where he studied angiogenesis.

  The price moved ahead of 20.39% from the mean of 20 days, 43.15% from mean of 50 days SMA and performed 35.35% from mean of 200 days price. Company’s performance for the week was 17.58%, 27.21% for month and YTD performance remained 84.76%.

Leave a Reply

Your email address will not be published. Required fields are marked *